Logo do repositório
 
Publicação

Avian Antibodies as Potential Therapeutic Tools

2025-03Recensão Acesso aberto
Ver registo simples
dc.contributor.authorEriksson, Mats
dc.contributor.authorEriksson, Mats
dc.contributor.authorLarsson, Anders
dc.contributor.authorLarsson, Anders
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblMDPI - Multidisciplinary Digital Publishing Institute
dc.date.accessioned2025-04-10T16:00:50Z
dc.date.available2025-04-10T16:00:50Z
dc.date.issued2025-03
dc.descriptionPublisher Copyright: © 2025 by the authors.
dc.description.abstractImmunoglobulin Y (IgY) is the primary antibody found in the eggs of chicken (Gallus domesticus), allowing for large-scale antibody production with high titers, making them cost-effective antibody producers. IgY serves as a valuable alternative to mammalian antibodies typically used in immunodiagnostics and immunotherapy. Compared to mammalian antibodies, IgY offers several biochemical advantages, and its straightforward purification from egg yolk eliminates the need for invasive procedures like blood collection, reducing stress in animals. Due to the evolutionary differences between birds and mammals, chicken antibodies can bind to a broader range of epitopes on mammalian proteins than their mammalian counterparts. Studies have shown that chicken antibodies bind 3–5 times more effectively to rabbit IgG than swine antibodies, enhancing the signal in immunological assays. Additionally, IgY does not interact with rheumatoid factors or human anti-mouse IgG antibodies (HAMA), helping to minimize interference from these factors. IgY obtained from egg yolk of hens immunized against Pseudomonas aeruginosa has been used in patients suffering from cystic fibrosis and chronic pulmonary colonization with this bacterium. Furthermore, IgY has been used to counteract streptococcus mutans in the oral cavity and for the treatment of enteral infections in both humans and animals. However, the use of avian antibodies is limited to pulmonary, enteral, or topical application and should, due to immunogenicity, not be used for systemic administration. Thus, IgY expands the range of strategies available for combating pathogens in medicine, as a promising candidate both as an alternative to antibiotics and as a valuable tool in research and diagnostics.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent2357130
dc.identifier.doi10.3390/antib14010018
dc.identifier.issn2073-4468
dc.identifier.otherPURE: 114326691
dc.identifier.otherPURE UUID: 278ff109-0cee-48db-b936-f23f7870f14a
dc.identifier.otherScopus: 105001139302
dc.identifier.urihttp://hdl.handle.net/10362/182077
dc.identifier.urlhttps://www.scopus.com/pages/publications/105001139302
dc.language.isoeng
dc.peerreviewedyes
dc.subjectantibiotics
dc.subjectantimicrobial resistance
dc.subjectcystic fibrosis
dc.subjectegg yolk
dc.subjectGallus gallus domesticus
dc.subjecthen
dc.subjectIgY
dc.subjectimmunoglobulin
dc.subjectPseudomonas aeruginosa
dc.subjectsnake venom
dc.subjectImmunology and Allergy
dc.subjectImmunology
dc.subjectDrug Discovery
dc.subjectSDG 3 - Good Health and Well-being
dc.titleAvian Antibodies as Potential Therapeutic Toolsen
dc.typereview
degois.publication.issue1
degois.publication.titleAntibodies
degois.publication.volume14
dspace.entity.typePublication
person.familyNameEriksson
person.familyNameLarsson
person.givenNameMats Bertil
person.givenNameAnders
person.identifier1409165
person.identifier.orcid0000-0002-3178-4210
person.identifier.orcid0000-0003-3161-0402
rcaap.rightsopenAccess
relation.isAuthorOfPublicationc5d5620c-9249-4400-b5c7-067e80438f94
relation.isAuthorOfPublication8e9959d2-954f-4fae-85b0-4dc61b6627cd
relation.isAuthorOfPublication.latestForDiscovery8e9959d2-954f-4fae-85b0-4dc61b6627cd

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
antibodies-14-00018.pdf
Tamanho:
2.25 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS - Artigos em revista internacional com arbitragem científica